A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PAP / pokeweed antiviral protein

[Related PubMed/MEDLINE]
Total Number of Papers: 119
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PAP  (>> Co-occurring Abbreviation)
Long Form:   pokeweed antiviral protein
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Pokeweed antiviral protein attenuates liver fibrosis in mice through regulating Wnt/Jnk mediated glucose metabolism. HA, HSC, Hyp, LN
2017 Expression of an RNA glycosidase inhibits HIV-1 transactivation of transcription. AP-1, HIV-1, TAR
2017 Plant Translation Initiation Complex eIFiso4F Directs Pokeweed Antiviral Protein to Selectively Depurinate Uncapped Tobacco Etch Virus RNA. RIP, SRL, TEV
2016 A small RNA targets pokeweed antiviral protein transcript. JA, RIPs
2016 The Pokeweed Leaf mRNA Transcriptome and Its Regulation by Jasmonic Acid. JA, RIP
2015 Arabidopsis Bax Inhibitor-1 inhibits cell death induced by pokeweed antiviral protein in Saccharomyces cerevisiae. PCD, RIPs
2015 Pokeweed antiviral protein restores levels of cellular APOBEC3G during HIV-1 infection by depurinating Vif mRNA. HIV-1, Vif
2015 Pokeweed antiviral protein, a ribosome inactivating protein: activity, inhibition and prospects. RIP, S/R
2015 Pokeweed antiviral protein: its cytotoxicity mechanism and applications in plant disease resistance. RIP
10  2015 Structural analysis of a type 1 ribosome inactivating protein reveals multiple L‑asparagine‑N‑acetyl‑D‑glucosamine monosaccharide modifications: Implications for cytotoxicity. RIPs
11  2014 An N-terminal fragment of yeast ribosomal protein L3 inhibits the cytotoxicity of pokeweed antiviral protein in Saccharomyces cerevisiae. SRL
12  2014 Pokeweed antiviral protein alters splicing of HIV-1 RNAs, resulting in reduced virus production. ---
13  2014 Sugar binding effects on the enzymatic reaction and conformation near the active site of pokeweed antiviral protein revealed by fluorescence spectroscopy. NAG
14  2013 Inhibition of Japanese encephalitis virus infection in vitro and in vivo by pokeweed antiviral protein. JEV
15  2013 Structural characteristic of folding/unfolding intermediate of pokeweed anti-viral protein revealed by time-resolved fluorescence. FRET, GuHCl
16  2012 Inhibition of pokeweed antiviral protein (PAP) by turnip mosaic virus genome-linked protein (VPg). RIP, VPg
17  2012 Pokeweed antiviral protein increases HIV-1 particle infectivity by activating the cellular mitogen activated protein kinase pathway. ---
18  2011 Pokeweed antiviral protein down-regulates Wnt/beta-catenin signalling to attenuate liver fibrogenesis in vitro and in vivo. HA, Hyp, LN
19  2011 [Cloning and expression of pokeweed antiviral protein gene from Phytolacca americana in Pichia pastoris and the study of apoptosis of human neuroglioma cells U251 induced by recombinant PAP]. ---
20  2010 Homodimerization of pokeweed antiviral protein as a mechanism to limit depurination of pokeweed ribosomes. ---
21  2009 Characterization of pokeweed antiviral protein binding to mRNA cap analogs: competition with nucleotides and enhancement by translation initiation factor iso4G. RIP, SRL
22  2009 Suppression of human T-cell leukemia virus I gene expression by pokeweed antiviral protein. HTLV-I
23  2008 Depurination of Brome mosaic virus RNA3 in vivo results in translation-dependent accelerated degradation of the viral RNA. BMV
24  2008 Depurination within the intergenic region of Brome mosaic virus RNA3 inhibits viral replication in vitro and in vivo. BMV
25  2008 Expression of pokeweed antiviral protein in mammalian cells activates c-Jun NH2-terminal kinase without causing apoptosis. JNK, rRNA
26  2008 Pokeweed antiviral protein region Gly209-Lys225 is critical for RNA N-glycosidase activity of the prokaryotic ribosome. KRN, RIP, RNG
27  2008 The ribosomal stalk is required for ribosome binding, depurination of the rRNA and cytotoxicity of ricin A chain in Saccharomyces cerevisiae. RIPs, RTA
28  2007 The C-terminus of pokeweed antiviral protein has distinct roles in transport to the cytosol, ribosome depurination and cytotoxicity. RIP
29  2007 Vinyldeoxyadenosine in a sarcin-ricin RNA loop and its binding to ricin toxin a-chain. 8-vA, 8vdA, RTA
30  2006 A novel interaction of pokeweed antiviral protein with translation initiation factors 4G and iso4G: a potential indirect mechanism to access viral RNAs. TE
31  2006 Pokeweed antiviral protein depurinates the sarcin/ricin loop of the rRNA prior to binding of aminoacyl-tRNA to the ribosomal A-site. ---
32  2006 Solution behavior of a novel biopharmaceutical drug candidate: a gonadotropin-toxin conjugate. GnRH
33  2005 CNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV). LCMV
34  2005 Evidence for retro-translocation of pokeweed antiviral protein from endoplasmic reticulum into cytosol and separation of its activity on ribosomes from its activity on capped RNA. ER, RIP, SRL
35  2005 Expression of a truncated form of ribosomal protein L3 confers resistance to pokeweed antiviral protein and the Fusarium mycotoxin deoxynivalenol. DON
36  2005 Pokeweed antiviral protein inhibits brome mosaic virus replication in plant cells. BMV
37  2004 A 13-week subchronic intravaginal toxicity study of pokeweed antiviral protein in mice. ---
38  2004 Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor. GnRH
39  2004 Generation of pokeweed antiviral protein mutations in Saccharomyces cerevisiae: evidence that ribosome depurination is not sufficient for cytotoxicity. ---
40  2004 High resolution X-ray structure and potent anti-HIV activity of recombinant dianthin antiviral protein. DAP
41  2004 Mucosal toxicity studies of a gel formulation of native pokeweed antiviral protein. ---
42  2003 Cytotoxic activity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors. GnRH
43  2003 Effect of GnRH conjugated to pokeweed antiviral protein on reproductive function in adult male dogs. ---
44  2003 Expression of pokeweed antiviral proteins in creeping bentgrass. ---
45  2003 GnRH-PAP hormonotoxin targets cytotoxicity to prostate cancer cell lines. ---
46  2003 Resistance mechanisms to plant viruses: an overview. PDR, PTGS
47  2003 Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity. anti-HIV, HIV-1, hu-PBL
48  2003 Translation Inhibition of Capped and Uncapped Viral RNAs Mediated by Ribosome-Inactivating Proteins. AMV, IRES, RIPs, S/R, SPMV, TBSV
49  2002 Pokeweed antiviral protein binds to the cap structure of eukaryotic mRNA and depurinates the mRNA downstream of the cap. RIP
50  2002 Pokeweed antiviral protein regulates the stability of its own mRNA by a mechanism that requires depurination but can be separated from depurination of the alpha-sarcin/ricin loop of rRNA. RIP
51  2001 A C-terminal deletion mutant of pokeweed antiviral protein inhibits programmed +1 ribosomal frameshifting and Ty1 retrotransposition without depurinating the sarcin/ricin loop of rRNA. PRF, S/R
52  2001 Active center cleft residues of pokeweed antiviral protein mediate its high-affinity binding to the ribosomal protein L3. RIP, SRL
53  2001 Binding interactions between the active center cleft of recombinant pokeweed antiviral protein and the alpha-sarcin/ricin stem loop of ribosomal RNA. ---
54  2001 Pokeweed antiviral protein: a potential nonspermicidal prophylactic antiviral agent. HIV
55  2000 A non-toxic pokeweed antiviral protein mutant inhibits pathogen infection via a novel salicylic acid-independent pathway. PR, S/R, SA
56  2000 A novel mechanism for inhibition of translation by pokeweed antiviral protein: depurination of the capped RNA template. BMV, PVX, S/R
57  2000 Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines. GnRH
58  2000 Expression of biologically active recombinant pokeweed antiviral protein in methylotrophic yeast Pichia pastoris. ---
59  2000 Modeling and alanine scanning mutagenesis studies of recombinant pokeweed antiviral protein. ---
60  1999 Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein. ---
61  1999 High-level expression and purification of biologically active recombinant pokeweed antiviral protein. ---
62  1999 Pokeweed antiviral protein accesses ribosomes by binding to L3. RPL3
63  1999 Pokeweed antiviral protein cleaves double-stranded supercoiled DNA using the same active site required to depurinate rRNA. AP, RIPs
64  1999 Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1. HIV, HIV-I, TMV
65  1999 X-ray crystallographic analysis of the structural basis for the interaction of pokeweed antiviral protein with guanine residues of ribosomal RNA. RIP
66  1999 X-ray crystallographic analysis of the structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and ribosomal RNA substrate analogs. RIP
67  1998 Antitumor activity of TP3(anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma. ---
68  1998 Crystal structure of pokeweed antiviral protein from seeds ofPhytolacca americana at 0.25 nm. ---
69  1998 Effect of N-terminal deletions on the activity of pokeweed antiviral protein expressed in E. coli. ---
70  1998 Rationale for the use of immunotoxins in the treatment of HIV-infected humans. DT, HIV, ITs, PE, RIPs
71  1998 The deoxyribonuclease activity attributed to ribosome-inactivating proteins is due to contamination. RIPs
72  1998 The low expression level of pokeweed antiviral protein (PAP) gene in Escherichia coli by the inducible lac promoter is due to inefficient transcription and translation and not to the toxicity of the PAP. SD
73  1998 The pokeweed antiviral protein specifically inhibits Ty1-directed +1 ribosomal frameshifting and retrotransposition in Saccharomyces cerevisiae. ---
74  1997 A ribosome-inactivating protein from Amaranthus viridis. IEF, TMV
75  1997 Actions of pokeweed antiviral protein on virus-infected protoplasts. RIPs
76  1997 C-terminal deletion mutant of pokeweed antiviral protein inhibits viral infection but does not depurinate host ribosomes. PVX
77  1997 cDNA cloning and expression of pokeweed antiviral protein from seeds in Escherichia coli and its inhibition of protein synthesis in vitro. ---
78  1997 Expression and activity of a recombinant chimeric protein composed of pokeweed antiviral protein and of human interleukin-2. IL-2
79  1997 Expression of a cDNA encoding Phytolacca insularis antiviral protein confers virus resistance on transgenic potato plants. PIP, RIPs, rPIP
80  1997 Expression of Pokeweed Antiviral Protein in Transgenic Plants Induces Virus Resistance in Grafted Wild-Type Plants Independently of Salicylic Acid Accumulation and Pathogenesis-Related Protein Synthesis. PAP-v
81  1997 Gene expression evidence indicates that nucleotides 507-513 and 1434-1440 in 16S rRNA are organized in close proximity on the Escherichia coli 30S ribosomal subunit. hCT
82  1997 Identification of a biological inactive complex form of pokeweed antiviral protein. PAPi
83  1997 Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials. ALL, AML
84  1997 Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. ---
85  1997 Plant resistance to fungal infection induced by nontoxic pokeweed antiviral protein mutants. PR
86  1996 Major structural differences between pokeweed antiviral protein and ricin A-chain do not account for their differing ribosome specificity. RIPs
87  1995 In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein. ---
88  1995 Isolation and characterization of pokeweed antiviral protein mutations in Saccharomyces cerevisiae: identification of residues important for toxicity. ---
89  1995 Production and characterization of monoclonal antibodies against the ribosome-inactivating protein PAP from Phytolacca americana. RIP
90  1995 Recognition determinants for proteins and antibiotics within 23S rRNA. ---
91  1995 Substrate recognition by ribosome-inactivating protein studied by molecular modeling and molecular electrostatic potentials. RIP
92  1995 The action of pokeweed antiviral protein and ricin A-chain on mutants in the alpha-sarcin loop of Escherichia coli 23S ribosomal RNA. RIPs, RTA
93  1994 Correlation between the activities of five ribosome-inactivating proteins in depurination of tobacco ribosomes and inhibition of tobacco mosaic virus infection. RIPs, TMV
94  1994 Pokeweed antiviral protein (PAP) mutations which permit E.coli growth do not eliminate catalytic activity towards prokaryotic ribosomes. RIPs
95  1994 Pokeweed antiviral protein inactivates pokeweed ribosomes; implications for the antiviral mechanism. RIPs
96  1993 Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein. HIV-1
97  1993 Broad-spectrum virus resistance in transgenic plants expressing pokeweed antiviral protein. ---
98  1993 In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. SCID
99  1993 Messenger-dependent action of the pokeweed antiviral protein and fusidic acid on in vitro Vicia sativa L. translation. ---
100  1993 The 2.5 A structure of pokeweed antiviral protein. RIPs